1. We are committed to conduct ourselves in a professional, business like fashion, recognizing our narrowly focused ‘Executive pay and Board governance” objective is best supported by facts rather than emotional frustration.
2. We acknowledge the otherwise strong operational performance by executive management that has:
o Successfully expanded its core products globally – notably, Thalomid, Revlimid and Vidaza
o Put in place the global distribution and approval infrastructure to support the rapid expansion of these products
o Continued to place significant emphasis of R&D investments and the furthering of its significant pipeline to ensure continued future biotechnology segment and S&P 500 leadership in revenue and operating profit growth rates.
3. Simply stated, our central objective is to install reasonable and measured executive compensation criteria, that properly aligns management’s interests with its shareholder’s financial objectives and long-term belief in the future of the company.
4. While we recognize the right of each individual shareholder to take whatever action they deem in their own best interest, we ask them to not refer to this group if they are not prepared to conduct themselves in keeping with #1, 2, and 3 above.